65 studies on Cagrilintide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 1,200 published third-party lab tests of Cagrilintide across 440 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.55%. Within this published corpus, 2 positive purity results were below 90%, and 39 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $14.20 | $10.50–$19.50 | $2.84 | 5 sources · 5 offers |
| 10 mg | $20.50 | $17.00–$29.00 | $2.05 | 6 sources · 6 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 269 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 25 | 99.41% | 0 of 25 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 21 | 99.65% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 18 | 99.67% | 0 of 16 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #100901 (99.86%) · #100612 (99.83%) · #101190 (99.79%) · #101216 (99.94%) · #101219 (99.86%) · #101262 (99.88%)
This meta-analysis provides compelling evidence that CagriSema, combining a GLP-1 receptor agonist (semaglutide) with an amylin analog (cagrilintide), offers a substantially more potent and effective treatment option …
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
The initiation of this Phase 1 trial is a significant step in the development of new treatments for obesity and overweight, conditions with a substantial global health burden. If NNC0174-1213 demonstrates a favorable …
Treatment with Cagrilintide resulted in profound and statistically significant reductions in body weight and substantial improvements across multiple metabolic markers. > The high-dose Cagrilintide group exhibited a r…
This comprehensive review underscores amylin's critical, yet often underutilized, potential as a therapeutic agent for diabesity. Its unique mechanisms, including appetite suppression and improved glucose regulation, …
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
The development of Amylin-LP1 represents a significant advancement in the therapeutic landscape for metabolic disorders, offering a potent and well-tolerated option. Its long-acting profile could greatly enhance patie…
Cagrisema represents a highly potent and promising new therapeutic option for individuals struggling with obesity, offering superior weight loss efficacy and improved metabolic parameters compared to current gold-stan…
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment landscape for obesity, potentially offering a more effective therapeutic option than current monotherapies. Cag…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
Free, no account — handy when you're working with Cagrilintide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account